BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 25194570)

  • 1. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.
    Herranz D; Ambesi-Impiombato A; Palomero T; Schnell SA; Belver L; Wendorff AA; Xu L; Castillo-Martin M; Llobet-Navás D; Cordon-Cardo C; Clappier E; Soulier J; Ferrando AA
    Nat Med; 2014 Oct; 20(10):1130-7. PubMed ID: 25194570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia.
    Yashiro-Ohtani Y; Wang H; Zang C; Arnett KL; Bailis W; Ho Y; Knoechel B; Lanauze C; Louis L; Forsyth KS; Chen S; Chung Y; Schug J; Blobel GA; Liebhaber SA; Bernstein BE; Blacklow SC; Liu XS; Aster JC; Pear WS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):E4946-53. PubMed ID: 25369933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
    Sanchez-Martin M; Ferrando A
    Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-ALL pathogenesis requires a NOTCH1-driven MYC enhancer.
    Cancer Discov; 2014 Nov; 4(11):OF17. PubMed ID: 25367958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias.
    Rakowski LA; Garagiola DD; Li CM; Decker M; Caruso S; Jones M; Kuick R; Cierpicki T; Maillard I; Chiang MY
    Cancer Res; 2013 Jan; 73(2):930-41. PubMed ID: 23161489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An oncogenic enhancer enemy (N-Me) in T-ALL.
    Herranz D; Ferrando AA
    Cell Cycle; 2015; 14(2):167-8. PubMed ID: 25584678
    [No Abstract]   [Full Text] [Related]  

  • 7. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.
    Matsushita K; Kitamura K; Rahmutulla B; Tanaka N; Ishige T; Satoh M; Hoshino T; Miyagi S; Mori T; Itoga S; Shimada H; Tomonaga T; Kito M; Nakajima-Takagi Y; Kubo S; Nakaseko C; Hatano M; Miki T; Matsuo M; Fukuyo M; Kaneda A; Iwama A; Nomura F
    Oncotarget; 2015 Mar; 6(7):5102-17. PubMed ID: 25671302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA3-Controlled Nucleosome Eviction Drives
    Belver L; Yang AY; Albero R; Herranz D; Brundu FG; Quinn SA; Pérez-Durán P; Álvarez S; Gianni F; Rashkovan M; Gurung D; Rocha PP; Raviram R; Reglero C; Cortés JR; Cooke AJ; Wendorff AA; Cordó V; Meijerink JP; Rabadan R; Ferrando AA
    Cancer Discov; 2019 Dec; 9(12):1774-1791. PubMed ID: 31519704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymocyte transformation enhanced.
    Pouliot GP; Gutierrez A
    Nat Med; 2014 Oct; 20(10):1096-7. PubMed ID: 25295936
    [No Abstract]   [Full Text] [Related]  

  • 10. Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL.
    Antoszewski M; Fournier N; Ruiz Buendía GA; Lourenco J; Liu Y; Sugrue T; Dubey C; Nkosi M; Pritchard CEJ; Huijbers IJ; Segat GC; Alonso-Moreno S; Serracanta E; Belver L; Ferrando AA; Ciriello G; Weng AP; Koch U; Radtke F
    Blood; 2022 Apr; 139(16):2483-2498. PubMed ID: 35020836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RUNX1 is required for oncogenic
    Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
    Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia.
    Choi SH; Severson E; Pear WS; Liu XS; Aster JC; Blacklow SC
    PLoS One; 2017; 12(10):e0185762. PubMed ID: 29023469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.
    Chiang MY; Wang Q; Gormley AC; Stein SJ; Xu L; Shestova O; Aster JC; Pear WS
    Blood; 2016 Nov; 128(18):2229-2240. PubMed ID: 27670423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
    Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
    Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to resist Notch-targeted T-leukemia therapy: Lineage- and MYC enhancer switch.
    Bayer M; Grosschedl R
    Mol Cell; 2022 Mar; 82(5):884-886. PubMed ID: 35245453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic regulation of the Ink4a-Arf (Cdkn2a) tumor suppressor locus in the initiation and progression of Notch1-driven T cell acute lymphoblastic leukemia.
    Volanakis EJ; Boothby MR; Sherr CJ
    Exp Hematol; 2013 Apr; 41(4):377-86. PubMed ID: 23178376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Tumor Suppressor Enhancer of
    Tottone L; Lancho O; Loh JW; Singh A; Kimura S; Roels J; Kuchmiy A; Strubbe S; Lawlor MA; da Silva-Diz V; Luo S; Gachet S; García-Prieto CA; Hagelaar R; Esteller M; Meijerink JPP; Soulier J; Taghon T; Van Vlierberghe P; Mullighan CG; Khiabanian H; Rocha PP; Herranz D
    Blood Cancer Discov; 2021 Jan; 2(1):92-109. PubMed ID: 33458694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
    Pajcini KV; Xu L; Shao L; Petrovic J; Palasiewicz K; Ohtani Y; Bailis W; Lee C; Wertheim GB; Mani R; Muthusamy N; Li Y; Meijerink JPP; Blacklow SC; Faryabi RB; Cherry S; Pear WS
    Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL.
    Piya S; Yang Y; Bhattacharya S; Sharma P; Ma H; Mu H; He H; Ruvolo V; Baran N; Davis RE; Jain AK; Konopleava M; Kantarjian H; Andreeff M; You MJ; Borthakur G
    Leukemia; 2022 May; 36(5):1261-1273. PubMed ID: 35173274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
    Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
    J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.